Second malignancies complicating Hodgkin's disease in remission

G. P. Canellos, J. C. Arseneau, V. T. DeVita, J. Whang-Peng, R. E. Johnson

Research output: Contribution to journalArticle

Abstract

The incidence of second tumors occurring in the course of Hodgkin's disease was investigated in a series of 452 patients treated with standard chemotherapy or radiotherapy, combination chemotherapy alone, intensive radiotherapy alone, or both intensive radiotherapy and combination chemotherapy administered in sequence. Sixteen tumors were noted. When analysed according to mode of treatment, 6 cases occurred in a group of 62 patients who received both modalities. When analysed for age, sex, and man years of followup, this group had 14.5 times the risk of developing a second tumor. However, that subgroup which had a complete remission after intensive radiotherapy followed by a relapse of disease, prior to receiving combination chemotherapy, had the highest risk with 18.5 times greater incidence of second tumor than expected. It is noteworthy that, of the 16 second tumors, 2 were acute myeloid leukemia; in both cases a similar chromosomal abnormality (45 chromosomes, C group deletion) was noted. The mechanism of oncogenesis may represent a combination of the immunosuppressive effects and cellular effects of those forms of treatment.

Original languageEnglish
Pages (from-to)947-949
Number of pages3
JournalLancet
Volume1
Issue number7913
DOIs
Publication statusPublished - Dec 1 1975
Externally publishedYes

Fingerprint

Second Primary Neoplasms
Hodgkin Disease
Radiotherapy
Combination Drug Therapy
Neoplasms
Chromosomes, Human, 6-12 and X
Incidence
Immunosuppressive Agents
Acute Myeloid Leukemia
Chromosome Aberrations
Carcinogenesis
Recurrence
Drug Therapy
Therapeutics

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Canellos, G. P., Arseneau, J. C., DeVita, V. T., Whang-Peng, J., & Johnson, R. E. (1975). Second malignancies complicating Hodgkin's disease in remission. Lancet, 1(7913), 947-949. https://doi.org/10.1016/S0022-0736(75)80022-7

Second malignancies complicating Hodgkin's disease in remission. / Canellos, G. P.; Arseneau, J. C.; DeVita, V. T.; Whang-Peng, J.; Johnson, R. E.

In: Lancet, Vol. 1, No. 7913, 01.12.1975, p. 947-949.

Research output: Contribution to journalArticle

Canellos, GP, Arseneau, JC, DeVita, VT, Whang-Peng, J & Johnson, RE 1975, 'Second malignancies complicating Hodgkin's disease in remission', Lancet, vol. 1, no. 7913, pp. 947-949. https://doi.org/10.1016/S0022-0736(75)80022-7
Canellos, G. P. ; Arseneau, J. C. ; DeVita, V. T. ; Whang-Peng, J. ; Johnson, R. E. / Second malignancies complicating Hodgkin's disease in remission. In: Lancet. 1975 ; Vol. 1, No. 7913. pp. 947-949.
@article{48c49776bb7c46558dea6780eab8ce8c,
title = "Second malignancies complicating Hodgkin's disease in remission",
abstract = "The incidence of second tumors occurring in the course of Hodgkin's disease was investigated in a series of 452 patients treated with standard chemotherapy or radiotherapy, combination chemotherapy alone, intensive radiotherapy alone, or both intensive radiotherapy and combination chemotherapy administered in sequence. Sixteen tumors were noted. When analysed according to mode of treatment, 6 cases occurred in a group of 62 patients who received both modalities. When analysed for age, sex, and man years of followup, this group had 14.5 times the risk of developing a second tumor. However, that subgroup which had a complete remission after intensive radiotherapy followed by a relapse of disease, prior to receiving combination chemotherapy, had the highest risk with 18.5 times greater incidence of second tumor than expected. It is noteworthy that, of the 16 second tumors, 2 were acute myeloid leukemia; in both cases a similar chromosomal abnormality (45 chromosomes, C group deletion) was noted. The mechanism of oncogenesis may represent a combination of the immunosuppressive effects and cellular effects of those forms of treatment.",
author = "Canellos, {G. P.} and Arseneau, {J. C.} and DeVita, {V. T.} and J. Whang-Peng and Johnson, {R. E.}",
year = "1975",
month = "12",
day = "1",
doi = "10.1016/S0022-0736(75)80022-7",
language = "English",
volume = "1",
pages = "947--949",
journal = "The Lancet",
issn = "0140-6736",
publisher = "Elsevier Limited",
number = "7913",

}

TY - JOUR

T1 - Second malignancies complicating Hodgkin's disease in remission

AU - Canellos, G. P.

AU - Arseneau, J. C.

AU - DeVita, V. T.

AU - Whang-Peng, J.

AU - Johnson, R. E.

PY - 1975/12/1

Y1 - 1975/12/1

N2 - The incidence of second tumors occurring in the course of Hodgkin's disease was investigated in a series of 452 patients treated with standard chemotherapy or radiotherapy, combination chemotherapy alone, intensive radiotherapy alone, or both intensive radiotherapy and combination chemotherapy administered in sequence. Sixteen tumors were noted. When analysed according to mode of treatment, 6 cases occurred in a group of 62 patients who received both modalities. When analysed for age, sex, and man years of followup, this group had 14.5 times the risk of developing a second tumor. However, that subgroup which had a complete remission after intensive radiotherapy followed by a relapse of disease, prior to receiving combination chemotherapy, had the highest risk with 18.5 times greater incidence of second tumor than expected. It is noteworthy that, of the 16 second tumors, 2 were acute myeloid leukemia; in both cases a similar chromosomal abnormality (45 chromosomes, C group deletion) was noted. The mechanism of oncogenesis may represent a combination of the immunosuppressive effects and cellular effects of those forms of treatment.

AB - The incidence of second tumors occurring in the course of Hodgkin's disease was investigated in a series of 452 patients treated with standard chemotherapy or radiotherapy, combination chemotherapy alone, intensive radiotherapy alone, or both intensive radiotherapy and combination chemotherapy administered in sequence. Sixteen tumors were noted. When analysed according to mode of treatment, 6 cases occurred in a group of 62 patients who received both modalities. When analysed for age, sex, and man years of followup, this group had 14.5 times the risk of developing a second tumor. However, that subgroup which had a complete remission after intensive radiotherapy followed by a relapse of disease, prior to receiving combination chemotherapy, had the highest risk with 18.5 times greater incidence of second tumor than expected. It is noteworthy that, of the 16 second tumors, 2 were acute myeloid leukemia; in both cases a similar chromosomal abnormality (45 chromosomes, C group deletion) was noted. The mechanism of oncogenesis may represent a combination of the immunosuppressive effects and cellular effects of those forms of treatment.

UR - http://www.scopus.com/inward/record.url?scp=0016699982&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0016699982&partnerID=8YFLogxK

U2 - 10.1016/S0022-0736(75)80022-7

DO - 10.1016/S0022-0736(75)80022-7

M3 - Article

VL - 1

SP - 947

EP - 949

JO - The Lancet

JF - The Lancet

SN - 0140-6736

IS - 7913

ER -